Implementation of pharmacogenetic testing in oncology: DPYD-guided dosing to prevent fluoropyrimidine toxicity in British Columbia

Background: Fluoropyrimidine toxicity is often due to variations in the gene (DPYD) encoding dihydropyrimidine dehydrogenase (DPD). DPYD genotyping can be used to adjust doses to reduce the likelihood of fluoropyrimidine toxicity while maintaining therapeutically effective drug levels.Methods: A mul...

Full description

Bibliographic Details
Published in:	Frontiers in Pharmacology
Main Authors:	Angela Wu, Helen Anderson, Curtis Hughesman, Sean Young, Caroline Lohrisch, Colin J. D. Ross, Bruce C. Carleton
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-09-01
Subjects:	adverse drug reactions clinical implementation DPYD fluoropyrimidine toxicity pharmacogenetics
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2023.1257745/full

Similar Items

Discovering novel germline genetic variants linked to severe fluoropyrimidine-related toxicity in- and outside DPYD
by: Jonathan E. Knikman, et al.
Published: (2024-08-01)

DPYD-guided fluoropyrimidine dose adjustment in colorectal cancer DPYD carriers: start slower to finish stronger
by: Rocío Rosas-Alonso, et al.
Published: (2025-09-01)

DPYD variant testing in candidates for fluoropyrimidine treatment: A study protocol
by: Ana Hernández-Guío, et al.
Published: (2021-05-01)

Novel Genetic Variants Explaining Severe Adverse Drug Events after Clinical Implementation of <i>DPYD</i> Genotype-Guided Therapy with Fluoropyrimidines: An Observational Study
by: Xando Díaz-Villamarín, et al.
Published: (2024-07-01)

Balance of care activity after EMA recommendation for DPYD gene testing in Galicia
by: Almudena Gil-Rodríguez, et al.
Published: (2025-03-01)

Poor association between dihydropyrimidine dehydrogenase (DPYD) genotype and fluoropyrimidine‐induced toxicity in an Asian population
by: Masashi Kanai, et al.
Published: (2023-04-01)

Implementing pharmacogenetic testing in fluoropyrimidine-treated cancer patients: DPYD genotyping to guide chemotherapy dosing in Greece
by: Georgia Ragia, et al.
Published: (2023-09-01)

DPYD Genotyping, Fluoropyrimidine Dosage and Toxicity: An Umbrella Review of Systematic Reviews
by: Sara Otero-Torres, et al.
Published: (2025-05-01)

The Frequency of <i>DPYD</i> c.557A>G in the Dominican Population and Its Association with African Ancestry
by: Mariela Guevara, et al.
Published: (2024-12-01)

Clinical implications of a gain-of-function genetic polymorphism in DPYD (rs4294451) in colorectal cancer patients treated with fluoropyrimidines
by: Elena De Mattia, et al.
Published: (2024-12-01)

DPYD genotype-guided dose personalisation for fluoropyrimidine-based chemotherapy prescribing in solid organ cancer patients in Australia: GeneScreen 5-FU study protocol
by: Cassandra White, et al.
Published: (2024-11-01)

Upfront <i>DPYD</i> Genotyping and Toxicity Associated with Fluoropyrimidine-Based Concurrent Chemoradiotherapy for Oropharyngeal Carcinomas: A Work in Progress
by: Antoine Desilets, et al.
Published: (2022-01-01)

Ten-year experience with pharmacogenetic testing for DPYD in a national cancer center in Italy: Lessons learned on the path to implementation
by: A. Bignucolo, et al.
Published: (2023-05-01)

<i>DPYD</i> Exon 4 Deletion Associated with Fluoropyrimidine Toxicity and Importance of Copy Number Variation
by: Theodore J. Wigle, et al.
Published: (2023-01-01)

A novel large intragenic DPYD deletion causing dihydropyrimidine dehydrogenase deficiency: a case report
by: Anna Malekkou, et al.
Published: (2024-03-01)

Clinical Relevance of Novel Polymorphisms in the Dihydropyrimidine Dehydrogenase (<i>DPYD</i>) Gene in Patients with Severe Fluoropyrimidine Toxicity: A Spanish Case-Control Study
by: Paula Soria-Chacartegui, et al.
Published: (2021-11-01)

Clinical Implementation of DPYD Pharmacogenetic Testing to Prevent Early-Onset Fluoropyrimidine-Related Toxicity in Cancer Patients in Switzerland
by: Ursina B. M. Begré, et al.
Published: (2022-05-01)

Implementing Pharmacogenetic Testing in Gastrointestinal Cancers (IMPACT-GI): Study Protocol for a Pragmatic Implementation Trial for Establishing DPYD and UGT1A1 Screening to Guide Chemotherapy Dosing
by: Lisa A. Varughese, et al.
Published: (2022-07-01)

Dihydropyrimidine Dehydrogenase Polymorphism c.2194G>A Screening Is a Useful Tool for Decreasing Gastrointestinal and Hematological Adverse Drug Reaction Risk in Fluoropyrimidine-Treated Patients
by: Alessio Ardizzone, et al.
Published: (2024-09-01)

Investigation of Ivs14+1G>A Polymorphism of Dpyd Gene in a Group of Bosnian Patients Treated with 5-Fluorouracil and Capecitabine
by: Timur Cerić, et al.
Published: (2010-05-01)

Pharmacogenomic-guided dosing of fluoropyrimidines beyond DPYD: time for a polygenic algorithm?
by: Anthi Maslarinou, et al.
Published: (2023-05-01)

Fluoropyrimidine-Induced Severe Toxicities Associated with Rare DPYD Polymorphisms: Case Series from Saudi Arabia and a Review of the Literature
by: Nedal Bukhari, et al.
Published: (2021-07-01)

Impact of pharmacogenomic DPYD variant guided dosing on toxicity in patients receiving fluoropyrimidines for gastrointestinal cancers in a high-volume tertiary centre
by: David K. Lau, et al.
Published: (2023-04-01)

Fluoropyrimidine chemotherapy: recommendations for DPYD genotyping and therapeutic drug monitoring of the Swiss Group of Pharmacogenomics and Personalised Therapy
by: Seid Hamzic, et al.
Published: (2020-11-01)

Pharmacogenetic Practice of Anticancer Drugs: Multiple Approaches for an Accurate and Comprehensive Genotyping
by: Montrasio C, et al.
Published: (2023-07-01)

Direct Health Care Costs Associated with Asthma in British Columbia
by: Mohsen Sadatsafavi, et al.
Published: (2010-01-01)

Implementation of DPYD testing in Bulgarian patients with cancer
by: Nelly Miteva-Marcheva, et al.
Published: (2024-12-01)

Pharmacogenomic tests in Oncology - finding the right dose
by: Jeziel Basso, et al.
Published: (2021-10-01)

Pharmacogenomic tests of oncology drugs at Instituto Nacional de Câncer (INCA)
by: Guilherme Suarez-Kurtz
Published: (2021-10-01)

Commentary: The pharmacogenomic landscape of an Indigenous Australian population
by: Cassandra White, et al.
Published: (2024-05-01)

Pharmacogenetic variants in TPMT alter cellular responses to cisplatin in inner ear cell lines.
by: Amit P Bhavsar, et al.
Published: (2017-01-01)

Toxic and Adverse Effects of Chemotherapy with 5-Fluoropyrimidine Drugs. Could Dihydropyrimidine Dehydrogenase Enzyme Screening Serve as a Prerequisite to Successful Chemotherapy?
by: Velko Minchev
Published: (2020-12-01)

Differences in <i>DPYD</i> Population Frequencies Observed in Galicians Compared to Europeans and Spanish from PhotoDPYD Study
by: Almudena Gil-Rodriguez, et al.
Published: (2025-04-01)

Review of Prodrug and Nanodelivery Strategies to Improve the Treatment of Colorectal Cancer with Fluoropyrimidine Drugs
by: Santu Sarkar, et al.
Published: (2024-05-01)

Importance of Rare DPYD Genetic Polymorphisms for 5-Fluorouracil Therapy in the Japanese Population
by: Eiji Hishinuma, et al.
Published: (2022-06-01)

Gemcitabine-Based versus Fluoropyrimidine-Based Chemotherapy and Role of Platinum Combination for First-Line Palliative Systemic Treatment in Advanced Ampullary Adenocarcinoma
by: Wonglhow J, et al.
Published: (2026-06-01)

The efficacy of fluoropyrimidine-based adjuvant chemotherapy on biliary tract cancer after R0 resection
by: Young Saing Kim, et al.
Published: (2017-01-01)

The polymeric fluoropyrimidine CF10 overcomes limitations of 5-FU in pancreatic ductal adenocarcinoma cells through increased replication stress
by: Jennifer M. Finan, et al.
Published: (2024-12-01)

Redefining the Incidence and Profile of Fluoropyrimidine-Associated Cardiotoxicity in Cancer Patients: A Systematic Review and Meta-Analysis
by: Yajie Lu, et al.
Published: (2023-03-01)

Life-Threatening Adverse Events Following Therapeutic Opioid Administration in Adults: Is Pharmacogenetic Analysis Useful?
by: Parvaz Madadi, et al.
Published: (2013-01-01)